NASDAQ$FLGT

Fulgent Genetics Inc. · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Fulgent Genetics' Q4 2021 earnings exceeded expectations, driven by strong core and COVID business performance.

Fulgent Genetics reported strong Q4 2021 results, with revenue of $251.7 million and core revenue growth of 234%. The company's GAAP income was $104.3 million, or $3.34 per share, and non-GAAP income was $108.7 million, or $3.48 per share.

  • Revenue totaled $251.7 million.
  • Billable tests delivered approximately 2.5 million.
  • Core Revenue grew 234% year-over-year to $40.1 million.
  • GAAP income was $104.3 million, or $3.34 per share.

Headline financials

Total Revenue

$252M

Previous: $295M-14.7%
EPS (adj)

$3.48

Previous: $6.20-43.9%
Net Income

$104M

Previous: $166M-37.3%
Operating Income

$151M

Previous: $226M-33.2%
Gross Profit

$190M

Previous: $243M-22.1%
Cash & Equivalents

$165M

Previous: $87.4M+88.6%
Total Assets

$1.28B

Previous: $700M+82.6%

Revenue & EPS history

Fulgent · Revenue · Quarterly

$252M

Q4 2021-14.7%vs Q4 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Fulgent · $40.1M total across 1 segment · Q4 2021

  • Core Revenue
    $40.1M

Forward guidance

For the first quarter of 2022, Fulgent Genetics expects total revenue of approximately $245 million and core revenue including COVID-19 NGS of approximately $32 million, representing growth of 92% year-over-year.

Tailwinds

  • Total Revenue of approximately $245 million
  • Core Revenue including COVID-19 NGS of approximately $32 million, representing growth of 92% year-over-year
  • Core Revenue excluding COVID-19 NGS of approximately $22 million
  • Total Revenue of approximately $600 million for full year 2022
  • Core Revenue excluding COVID-19 NGS of approximately $120 million for full year 2022

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-2.5%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-1.3%

Avg return

30 days after

37%

15 / 41 earnings

Positive

+38.3%

Q3 2019

Best reaction

-38.1%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-7.0%-1.8%+19.2%
Q4 2025-38.1%-43.5%-37.0%
Q3 2025+18.3%+30.3%+24.6%
Q1 2025+18.7%+8.1%+20.1%
Q4 2024-1.5%+6.1%+8.7%
Q3 2024-9.0%-16.3%-8.8%
Q2 2024+0.4%-0.3%-4.3%
Q1 2024+1.2%+0.1%-2.8%
Q4 2023-11.5%-6.8%-14.8%
Q3 2023+14.0%+11.1%+15.5%
Q2 2023-15.4%-18.1%-18.6%
Q1 2023+16.1%+23.4%+41.4%
Q4 2022-2.5%+3.3%-9.1%
Q3 2022-8.6%+3.3%-2.4%
Q2 2022-4.9%-20.4%-33.9%
Q1 2022+4.4%-4.1%-1.6%
Q4 2021-1.3%+0.1%-2.1%
Q3 2021-1.1%+10.5%+4.3%
Q2 2021-8.0%-10.9%-15.2%
Q1 2021+3.9%-2.5%+2.6%
Q4 2020-0.5%+18.1%+8.3%
Q3 2020-17.0%+6.9%+20.0%
Q2 2020+27.2%+26.1%+13.2%
Q1 2020-21.0%+3.9%+10.3%
Q4 2019-32.3%-42.6%-29.1%
Q3 2019+38.3%+68.1%+26.0%
Q2 2019+31.9%+45.4%+46.7%
Q1 2019-15.8%-16.5%-11.3%
Q4 2018+9.6%+7.6%+29.3%
Q3 2018+6.9%+12.3%+2.8%
Q2 2018-0.8%-4.9%-17.9%
Q1 2018-0.3%-2.3%-4.9%
Q4 2017-9.1%-20.9%-15.6%
Q3 2017+0.4%-4.0%+0.9%
Q2 2017-15.6%-9.9%-16.4%
Q1 2016-31.1%-30.0%-53.4%
Q1 2017-33.1%-29.4%-53.9%
Q2 2016-3.8%-9.0%-7.5%
Q4 2016+1.1%-4.2%-2.9%
Q4 2015-1.6%-1.7%+8.2%
Q3 2016-3.1%-4.1%+9.5%
Q3 2015
Q2 2015
Q1 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro